Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...
William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...
3d
Fintel on MSNWilliam Blair Upgrades Genmab A (GMAB)Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...
Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...
Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform. As of March 4, 2025, the average one-year price target ...
On Tuesday, William Blair analysts revised their stance on Genmab A/S (NASDAQ:GMAB), upgrading the stock from Market Perform to Outperform. The upgrade followed Genmab’s announcement on Monday ...
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Despite the setback with HexaBody-CD38, William Blair upgraded Genmab’s stock rating from Market Perform to Outperform, citing the company’s promising pipeline, including treatments like ...
Despite the setback with HexaBody-CD38, William Blair upgraded Genmab’s stock rating from Market Perform to Outperform, citing the company’s promising pipeline, including treatments like Epkinly and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results